The Asia Pacific Continuous Glucose Monitoring Device Market would witness market growth of 13.7% CAGR during the forecast period (2020-2026).
As tested in many clinical studies, it has been found that diabetic patients with type 1 diabetes mellitus (T1DM) with continuous glucose monitoring have greater glycemic regulation relative to when using glucometer for daily blood glucose self-monitoring. The trend follows in children, as well as those who frequently use a CGM. The results in these children display better-glycosylated levels of hemoglobin (HbA1c) without an increased hyperglycemia frequency.
The latest CGM models have enabled the administration of electrochemical subcutaneous sensors based on glucose oxidase to measure glucose levels in the interstitial fluid. CGM apps may either show the patterns in blood glucose levels retrospectively by downloading the data or offer a real-time image of glucose levels via receiver displays. Many CGMs in real-time can provide patients, parents, or caregivers with an alert during current or pending glycemic visits to encourage timely blood glucose control.
Asia Pacific market is predicted to have the fastest growth over the projected period. Nearly 60 percent of the world’s diabetic population lives in the Asia Pacific region, according to the Asian Diabetes Prevention Initiative. The high prevalence of the disease has spurred global demand development in developed countries such as India and China. In addition, increasing healthcare spending, extensive business activity, and supportive regulatory policies will have a positive effect on the development of this region’s market.
Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Based on End User, the market is segmented into Hospitals, Homecare Settings and Other End Users. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson
Scope of the Study
- Transmitters and
By End User
- Homecare Settings and
- Other End Users
- South Korea
- Rest of Asia Pacific
- Abbott Laboratories
- Medtronic PLC
- F. Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- DexCom, Inc.
- Ypsomed AG
- Senseonics Holdings, Inc.
- GlySens, Incorporated
- A. Menarini Diagnostics Ltd. (The Menarini Group)
- Echo Therapeutics, Inc.
- Johnson and Johnson
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free